Where your sodium actually comes from
About 71% of dietary sodium arrives via processed and restaurant food — the saltshaker accounts for 6–20%. The gap matters for how any reduction target is designed.
Vol. I, No. 142 · Friday, June 13, 2026 · Evidence-led medical research news
Contents — Issue 142
A tool compound strips the DNA-repair proteins tumors use to dodge PARP inhibitors. Preclinical only — but the gap between treated and control animals is the story.
Preclinical results; not yet peer-reviewed.
About 71% of dietary sodium arrives via processed and restaurant food — the saltshaker accounts for 6–20%. The gap matters for how any reduction target is designed.
A 27-year regulatory lag on a UV-filter already standard across the EU. What the approval timeline reveals about how the FDA handles cosmetic-grade actives.
Antibodies that sequester fentanyl before it crosses the blood-brain barrier. Defense funding, a novel adjuvant formulation, and a supply crisis that changes the risk calculus.
A new therapeutic target downstream of amyloid, premised on the contested idea that plaque accumulation is effect rather than cause. The trial design that tests the hypothesis.
Omega-3 supplementation shifted regulatory T-cell populations in an NOD mouse model; the mechanism points toward prostaglandin pathways. Animal data; human extrapolation is speculative.
The trial failed on progression-free survival. The sponsor’s communications team surfaced a subgroup. The subgroup was not pre-specified.
A proposed shelf-positioning rule affecting every major grocer rests on a single observational study with 340 participants and no randomization. The policy timeline presses ahead regardless.